Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2024 21:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Liquidia, Napco, and Franklin and Encourages Investors to Contact the Firm

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Liquidia Corporation...
September 16, 2024 21:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, Centuri, Liquidia, and Elastic and Encourages Investors to Contact the Firm

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Paragon 28, Inc. (NYSE:...
August 27, 2024 22:00 ET | Source: Bragar Eagel & Squire

LIQUIDIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Liquidia Corporation...
January 07, 2019 07:00 ET | Source: Liquidia Technologies, Inc.

Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial

LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
November 27, 2018 16:45 ET | Source: Liquidia Technologies, Inc.

Liquidia Technologies Provides Leadership Update

RESEARCH TRIANGLE PARK, N.C., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
November 14, 2018 16:30 ET | Source: Liquidia Technologies, Inc.

Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO

RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
November 14, 2018 08:00 ET | Source: Liquidia Technologies, Inc.

Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting

RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
November 09, 2018 08:00 ET | Source: Liquidia Technologies, Inc.

Liquidia Technologies to Present at Jefferies London Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
October 31, 2018 07:00 ET | Source: Liquidia Technologies, Inc.

Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...
October 23, 2018 08:00 ET | Source: Liquidia Technologies, Inc.

Liquidia Technologies to Provide Third Quarter 2018 Corporate Update on October 31, 2018

RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development...

Next Page keyboard_arrow_right